Factors influencing the risk of recurrence in patients with esophageal carcinoma treated with surgery: A single institution analysis consisting of 1002 cases

Xu,Yaping; Chen,Qixun; Yu,Xinmin; Zhou,Ximing; Zheng,Xiao; Mao,Weimin

doi:10.3892/ol.2012.1007

Factors influencing the risk of recurrence in patients with esophageal carcinoma treated with surgery: A single institution analysis consisting of 1002 cases

Authors:
- Yaping Xu
- Qixun Chen
- Xinmin Yu
- Ximing Zhou
- Xiao Zheng
- Weimin Mao
View Affiliations

Affiliations: Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, P.R. China, Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, P.R. China, Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, P.R. China
Published online on: October 30, 2012 https://doi.org/10.3892/ol.2012.1007
Pages: 185-190

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to identify the risk of recurrence in patients with thoracic esophageal squamous cell carcinoma (TESCC) treated with curative surgery. The retrospective analysis included 1002 consecutive patients with TESCC who had been treated with curative surgery in Zhejiang Cancer Hospital, China, between 2003 and 2008. Univariate and multivariate analyses using the Kaplan-Meier method and Cox proportional hazards model, respectively, were performed to identify the independent risk factors for locoregional recurrence and all the recurrence events. The 2- and 5-year recurrence rates were 39.0 and 59.2%, respectively. More than 85% of recurrences occurred within 36 months. The variables associated with a higher rate of recurrence in the univariate analysis were gender (male), length of tumor (≥5 cm), depth of invasion (deeper), lymph node metastasis (greater), histological grade (higher) and vessel involvement (positive). By multivariate analyses, gender (HR, 1.7; 95% CI, 1.2‑2.5; P=0.002), depth of invasion (HR, 1.4; 95% CI, 1.2‑1.6; P<0.001) and lymph node involvement (HR, 1.4; 95% CI, 1.3‑1.5; P<0.001) were independent predictive factors of recurrence. Post-operative radiotherapy or chemotherapy did not significantly prolong failure-free survival (FFS), particularly in patients with early-stage disease. Information regarding the depth of primary tumor invasion and the number of lymph nodes involved may help in evaluating the recurrence risk in patients with TESCC treated with curative surgery. Further studies are required to clarify the correlation between recurrence and the different multidisciplinary treatment approaches.

View Figures

View References

1	Guo M, Zhao YD, Yang HJ and Yan XF: Analysis of clinicopathological characteristics for 5406 cases of esophageal neoplasm. Chin J Cancer Prev Treat. 15:54–56. 2008.
2	Debevec L, Jeric T, Kovac V, et al: Is there any progress in routine management of lung cancer patients? A comparative analysis of an institution in 1996 and 2006. Radiol Oncol. 43:47–53. 2009. View Article : Google Scholar
3	Kovac V, Zwitter M and Zagar T: Population-based survey of malignant pleural mesothelioma in Slovenia: improved survival after introduction of chemotherapy. Radiol Oncol. 46:136–144. 2012. View Article : Google Scholar : PubMed/NCBI
4	Law SY, Fok M and Wong J: Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg. 83:107–111. 1996. View Article : Google Scholar : PubMed/NCBI
5	Bhansali MS, Fujita H, Kakegawa T, et al: Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg. 21:275–281. 1997. View Article : Google Scholar : PubMed/NCBI
6	Osugi H, Takemura M, Takada N, et al: Prognostic factors after esophagectomy and extended lymphadenectomy for squamous esophageal cancer. Br J Surg. 89:909–913. 2002. View Article : Google Scholar : PubMed/NCBI
7	Rice TW, Rusch VW, Ishwaran H, et al; Worldwide Esophageal Cancer Collaboration: Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Staging Manuals. Cancer. 116:3763–3773. 2010. View Article : Google Scholar
8	Dresner SM and Griffin SM: Pattern of recurrence following radical esophagectomy with two-field lymphadenectomy. Br J Surg. 87:1426–1433. 2000. View Article : Google Scholar : PubMed/NCBI
9	Isono K, Sato H and Nakayama K: Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology. 48:411–420. 1991. View Article : Google Scholar : PubMed/NCBI
10	Dixit S, Tilston M and Peter WM: Risk stratification for recurrence in patients with esophageal and junctional carcinoma treated with neoadjuvant chemotherapy and surgery. Med Oncol. 27:242–248. 2010. View Article : Google Scholar : PubMed/NCBI
11	Matsubara T, Ueda M, Nagao N, et al: Cervicothoracic approach for total mesesophageal dissection in cancer of the thoracic esophagus. J Am Coll Surg. 187:238–245. 1998. View Article : Google Scholar : PubMed/NCBI
12	Altorki NK and Skinner DB: Occult cervical nodal metastasis in esophageal cancer: preliminary results of three-field lymphadenectomy. J Thorac Cardiovasc Surg. 113:540–544. 1997. View Article : Google Scholar : PubMed/NCBI
13	Shiozaki H, Yano M, Tsujinaka T, et al: Lymph node metastasis along the recurrent nerve chain is indication for cervical lymph node dissection in thoracic esophageal cancer. Dis Esophagus. 14:191–196. 2001. View Article : Google Scholar : PubMed/NCBI
14	Chen J, Liu S, Pan J, et al: The pattern and prevalence of lymphatic spread in thoracic oesophageal squamous cell carcinoma. Eur J Cardiothorac Surg. 36:480–486. 2009. View Article : Google Scholar : PubMed/NCBI
15	Ando N, Iizuka T, Ide H, et al; Japan Clinical Oncology Group: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG9204. J Clin Oncol. 21:4592–4596. 2003. View Article : Google Scholar : PubMed/NCBI
16	Pouliquen X, Levard H, Hay JM, et al: 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial French Associations for Surgical Research. Ann Surg. 223:127–133. 1996. View Article : Google Scholar
17	Lee J, Lee KE, Im YH, et al: Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 80:1170–1175. 2005. View Article : Google Scholar : PubMed/NCBI
18	Heroor A, Fujita H, Sueyoshi S, et al: Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study. Dig Surg. 20:229–235; discussion. 236–237. 2003. View Article : Google Scholar : PubMed/NCBI
19	Shiozaki A, Yamagishi H, Itoi H, et al: Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer. Oncol Rep. 13:667–672. 2005.PubMed/NCBI
20	Bystricky B, Okines AF and Cunningham D: Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer. Drugs. 71:541–555. 2011. View Article : Google Scholar : PubMed/NCBI
21	Zhang J, Chen HQ, Zhang YW, et al: Adjuvant chemotherapy in oesophageal cancer: a meta-analysis and experience from the Shanghai Cancer Hospital. J Int Med Res. 36:875–882. 2008. View Article : Google Scholar : PubMed/NCBI
22	Lu JC, Qian PD, Zha WW, et al: The meta-analysis of randomized controlled trial of prophylactic radiotherapy for esophageal carcinoma after curative resection. J Evid Based Med. 5:166–171. 2005.
23	Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345:725–730. 2001. View Article : Google Scholar
24	Gaast AV, van Hagen P, Hulshof M, et al: Esophagogastric junction cancer: Results from a multicenter randomized phase III study. J Clin Oncol (Meeting Abstracts). 28:40042010.